DOSE RESPONSE STUDY OF BG9273(LFA 3 & IGG1 FUSION PROTEIN)

待检验的假设是，LFA-III IgG 1融合蛋白预防T细胞活化将对斑块状银屑病患者产生有益的治疗效果。 克鲁格博士设计的一项多中心研究已经启动，计划在犹他州中心招募10名患者。所有中心将入组200例患者，目标是160例受试者完成至少8周的治疗。 待测药物是一种二聚体蛋白，含有LFA-III的第一个胞外结构域，融合至人IgG 1的铰链片段和恒定区。 LFA-III部分结合T细胞上的CD 2受体，IgG 1部分结合抗原呈递细胞上的Fc受体。 该分子被设计为通过阻断由皮肤的抗原呈递细胞上表达的共刺激分子介导的增强的抗原呈递能力来阻断T细胞活化。初步证据表明，该药物是安全的，但尚未对疗效数据进行分析。

The hypothesis to be tested is that prevention of T-cell activation by LFA-III IgG1 fusion protein will have a beneficial therapeutic effect in patients with plaque psoriasis. A multicenter study designed by Dr. Krueger has been mounted, with plans to enroll ten patients at the Utah Center. Two-hundred patients will be enrolled in all centers, with a goal of having 160 subjects complete at least eight weeks of therapy. The agent to be tested is a dimeric protein containing the first extracellular domain of LFA-III fused to the hinged segment and constant regions of human IgG1. The LFA-III portion binds the CD2 receptor on T-cells, and the IgG1 portion binds to the Fc receptor on antigen-presenting cells. The molecule was designed to block T-cell activation by blocking the enhanced antigen-presenting capacity mediated by the co-stimulatory molecules expressed on antigen-presenting cells of the skin. Preliminary evidence suggests that the agent is safe, but efficacy data have not yet been analyzed.